<DOC>
	<DOCNO>NCT01217359</DOCNO>
	<brief_summary>Purpose : The purpose exploratory study evaluate phosphoprotein profile determine difference intracellular action interferon interferon stimulate gene among people different treatment outcome interferon base therapy hepatitis C ( HCV ) . Participants : Patients genotype 1 HCV interferon base therapy University North Carolina ( UNC ) . Procedures : Thirty patient varied response treatment give single subcutaneous injection interferon alpha 2b . Prior injection 30 minute , 1,2,4,6,12 20 hour injection , blood drawn analysis phosphoprotein profile change serum cytokine .</brief_summary>
	<brief_title>Differences Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>To eligible study , subject must meet follow inclusion criterion : Willing able provide inform consent Males females age 18 65 year For woman childbearing potential , negative blood pregnancy test document within 24hour period prior IFNÎ± administration History genotype 1 HCV infection previously treat peginterferon ribavirin virological response determine retrospective review medical record A washout period &gt; 12 week last dose prescribe peginterferon ribavirin screen visit Exclusion Criteria Subjects follow eligible participation : Neutrophil count &lt; 1500 cells/mm3 , Hgb &lt; 12 g/dL woman 13 g/dL men , platelet count &lt; 75,000 cells/mm3 screen Serum creatinine level &gt; 1.5 time upper limit normal screen Poorly control psychiatric illness , determine study physician , exacerbate interferon therapy Infection require antibiotic , symptomatic viral infection , inflammatory process require therapy , allergic reaction week immediately precede inpatient study visit Use medication affect immune system ( e.g . glucocorticoid , chronic NSAIDs daily ) week immediately precede inpatient study visit History immunologically mediate disease ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , psoriasis , rheumatoid arthritis ) Women ongoing pregnancy breastfeed History evidence bleed esophageal varix condition consistent decompensated liver disease History seizure disorder current anticonvulsant use History major organ transplantation exist functional graft History thyroid disease poorly control prescribed medication History evidence severe illness condition would make patient , opinion investigator , unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>